Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.43 |
| ▸ | TDP2 | O95551 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13872303 | 0.88 | MAP3K5 (0.43) | MAP3K5CYP11B2TDP2CYP11B1CYP1A2 | |
| SCHEMBL13113755 | 0.88 | MCHR1 (0.48) | MAP3K5MCHR1CYP3A4CYP2C19 | |
| SCHEMBL3481109 | 0.85 | MAP3K5 (0.51) | MAP3K5CYP11B2TDP2CYP11B1CYP1A2 | |
| SCHEMBL13113569 | 0.83 | MAP3K5 (0.51) | MAP3K5CYP11B2TDP2CYP11B1CYP1A2 | |
| SCHEMBL13871907 | 0.78 | MAP3K5 (0.49) | MAP3K5CYP11B2TDP2CYP11B1CYP1A2 | |
| SCHEMBL13113748 | 0.78 | HTR2C (0.47) | MAP3K5CYP11B2CYP11B1CYP1A2CYP3A4 | |
| SCHEMBL13113768 | 0.78 | NPC1 (0.39) | MAP3K5TDP2CYP3A4CYP2C19 | |
| SCHEMBL13113735 | 0.76 | NPC1 (0.49) | CYP1A2MCHR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13872280 | 0.75 | MCHR1 (0.36) | MAP3K5MCHR1 | |
| SCHEMBL13113777 | 0.73 | MAP3K5 (0.48) | MAP3K5MCHR1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, SYNCRIP, RNMT | MAP3K5 4170/4885CYP11B2 2631/4885TDP2 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.